Author Archives: Lu Rahman

Accelerating cellular therapy discovery with the next generation BioELN

Cellular therapeutics like CAR-T have revolutionised cancer treatment and hold immense promise in other areas of unmet medical need. Developing a new therapeutic cell line is no small task and requires the design and tracking of molecular tools, viral vectors, pluripotent stem cells and more. With projects spanning weeks and… Read More

Webinar date:
Brought to you by PerkinElmer Informatics
#Webinars

#Biomedical research #Cancer #Cannabinoid #Oncology #Plant-based

Can cannabis and mushroom-based products eliminate colon cancer cells?

Cannabotech, a biomedical company developing oncological products based on cannabis and mushroom extracts, reports cell model study results showing that its ‘integrative-colon’ products killed over 90% of colon cancer cells. These products are based on a combination of several cannabinoids from the cannabis plant and various mushroom extracts. The study… Read More

#Cancer Research #Editor's Choice #News #Trending News

#Biopharmaceuticals #Covid-19 #Drug discovery #Pharmaceutical #Therapeutics #Women in STEM

International Women’s Day: Female achievement in drug discovery

The theme for International Women’s Day 2022 is ‘Break the Bias’, in which society is encouraged to celebrate women's achievements, in turn raising awareness against bias and inspiring positive action for equality. Though the initiative is interdisciplinary, the drug discovery, life science and pharmaceutical world boasts many achievements of this… Read More

#Editor's Choice #Exclusive Content #News #Opinion #Trending News

#Drug design #Drug discovery #Hotspot mapping

How hotspot mapping can accelerate early-phase drug design

In a recent paper in the Journal of Chemical Information and Modeling, authors from the Cambridge Crystallographic Data Centre (CCDC), Exscientia, and Oxford University show how an automated process leveraging “ensemble hotspot maps” can identify key structural differences that contribute to the selectivity of a compound for one protein over… Read More

#Editor's Choice #News

#AI / data analytics / healthtech / informatics #BioELN #Cell therapy

Webinar: Accelerating cellular therapy discovery with BioELN

Cellular therapeutics like CAR-T have revolutionised cancer treatment and hold immense promise in other areas of unmet medical need. Developing a new therapeutic cell line is no small task and requires the design and tracking of molecular tools, viral vectors, pluripotent stem cells and more. With projects spanning weeks and… Read More

#News

#Lab automation #Lab of the future #Liquid handling

Lab of the future: an expert view

The Lab of the Future will fuse automation, speed and remote work says Thomas Marshall, Senior Staff Research Scientist at Beckman Coulter Life Sciences. Labs across research areas—life sciences, pharma, and biotech—were already becoming remarkably automated but the pandemic has spurred a new kind of urgency in automating both individual… Read More

#Exclusive Content #News #Trends & Analysis

Kill the tumour, spare the healthy tissue. Ultra high-content imaging enables target discovery for CAR T cell therapy

In this free webinar, Dr. Christoph Herbel presents a newly developed workflow which combines flow cytometry–based screenings with high-parameter imaging to identify and validate new tumour markers in an unbiased approach.   The event, Kill the tumour, spare the healthy tissue. Ultra high-content imaging enables target discovery for CAR T cell therapy, was hosted by DDW and supported by Miltenyi Biotec.  It… Read More

Webinar date:
Brought to you by Miltenyi Biotec
#Webinars

#AI / data analytics / healthtech / informatics #Drug design

Iktos and Chiesi Group in AI drug design collaboration

Iktos, which specialises in artificial intelligence (AI) for new drug design, is teaming up with Chiesi Group. Under the agreement, Iktos’s de novo generative design software Makya will be used by Chiesi scientists for the design of novel compounds and to accelerate hit-to-lead/lead optimisation. Iktos’ AI technology, based on deep generative models,… Read More

#News

#Antibodies #Covid-19 #Nanobodies #Therapeutics

Can llama antibodies help develop a Covid-19 therapy?

Amid the growing threat of a new and potentially more dangerous SARS-CoV-2 variant, scientists are ramping up the quest for Covid treatments. A recent study demonstrates the therapeutic potential of an unusual class of immune proteins: miniature antibodies called nanobodies, derived from llamas. Rockefeller University scientists Michael P. Rout and Brian T. Chait and… Read More

#Covid-19 #Editor's Choice #News

#Covid-19 #Immunology / Virology & Vaccines #Plant-based

First plant-based Covid-19 vaccine promising says Medicago and GSK

Results from the Phase III placebo-controlled efficacy study of Medicago’s plant-based Covid-19 vaccine candidate in combination with GlaxoSmithKline’s pandemic adjuvant have shown positive results. Vaccine efficacy was demonstrated in an environment dominated by SARS-CoV-2 variants, unlike most published Phase III efficacy trials for currently licensed Covid-19 vaccines that were conducted… Read More

#Editor's Choice #News #Trending News

#Covid-19 #Monoclonal antibodies #Reagents #Research

Sino Biological launches panel of research reagents for Omicron variant

Sino Biological has launched a panel of research reagents for the newly identified Omicron variant (B.1.1.529) of the SARS-CoV-2 virus. The new Omicron product line includes recombinant Omicron spike proteins (RBD, S1, and S-ECD trimer), monoclonal antibodies recognising the Omicron spike protein, and the Omicron pseudovirus assay CRO service. These… Read More

#News

#Covid-19 #FDA

FDA authorises Eli Lilly Covid therapy for under-12s

Paediatric patients from birth to 12 years old can now be treated with an antibody drug for Covid-19. The US Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab and etesevimab to be administered together in high-risk paediatric patients for the treatment of mild to… Read More

#Covid-19 #News

#AI / data analytics / healthtech / informatics #Biopharmaceutical #Drug discovery #Machine learning

The value of scientific intelligence in drug discovery

Leif Pedersen, President, Software, and David Lowis, Executive Director of Scientific Informatics at Certara, explain how scientific intelligence can refine and increase the effectiveness of critical decision points in drug discovery. Strong scientific intelligence capabilities are essential building blocks for a scientific informatics strategy and will increase the effectiveness of… Read More

#Exclusive Content #News

#Antivirals #Covid-19 #Drug discovery

Covid-19 antiviral pill cuts hospitalisation and deaths in half

If authorised, molnupiravir could be the first oral antiviral medicine for Covid-19. Merck (known as MSD outside the United States and Canada) and Ridgeback Biotherapeutics have announced that molnupiravir, an investigational oral antiviral medicine, significantly reduced the risk of hospitalisation or death at a planned interim analysis of the Phase… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Blood cancer #Cancer research #Collaboration #Oncology

New cancer ‘inhibitor’ could lead to improved treatment options

Researchers have discovered a potential advancement in the treatment of chronic myeloid leukaemia (CML), which they hope will one day offer an improved option for treating patients with this form of blood cancer. The study– published in Science Translational Medicine and led by the University of Glasgow in collaboration with… Read More

#Cancer Research #Editor's Choice #News #Trending News